Latest Period
Q2 2026
Security Snapshot
Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD) Institutional Ownership
CUSIP: 54948X109
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
79
Shares (Excl. Options)
33,040,099
Price
$1.07
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- LUCD on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 33,040,099
- Total 13F value
- $35,350,434
- Portfolio coverage rank
- 0%
- Share change
- +11,085,123
- Value change
- +$11,854,850
- Number of holders
- 79
- Shares outstanding
- 141,152,375
- SEC-reported price per share
- $0.99
- Insider filing price
- $0.99
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LUCD - Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 54948X109.
- 79 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 103 to 79 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $40,959,176 to $35,350,434.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 79 institutions filings for Q2 2026.
Security key
54948X109
Latest holder period
Q2 2026
13F holders
79
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
LUCD full holder history
Lucid Diagnostics Inc. SEC filings
Lucid Diagnostics Inc. company facts
Lucid Diagnostics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 54948X109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
LUCD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| PAVmed Inc. | 28% | -2.9% | $46,192,115 | 38,816,903 | 0% | PAVmed Inc. | 03 Feb 2026 | |
| Ayrton Capital LLC | 2% | $1,596,645 | 1,200,485 | Ayrton Capital LLC | 31 Dec 2024 |
As of 30 Jun 2026, 79 institutional investors reported holding 33,040,099 shares of Lucid Diagnostics Inc. - Common Stock, par value $0.001 per share (LUCD). This represents 23% of the company’s total 141,152,375 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
41%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 6.3% | 8,856,844 | 0.02% | $9,476,823 | |
| BlackRock, Inc. | 5.9% | 8,373,117 | +81% | 0% | $8,959,235 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6% | 6,556,344 | +58% | 0% | $7,015,288 |
| Two Seas Capital LP | 4.3% | 6,000,000 | +100% | 0.25% | $6,420,000 |
| MASTERS CAPITAL MANAGEMENT LLC | 2.8% | 4,000,000 | 0% | 0.6% | $4,280,000 |
| Aberdeen Group plc | 2.7% | 3,822,997 | +4.9% | 0.01% | $4,090,607 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7% | 3,789,948 | +69% | 0% | $4,055,874 |
| STATE STREET CORP | 1.7% | 2,437,337 | +57% | 0% | $2,607,951 |
| FIRST MANHATTAN CO. LLC. | 1.6% | 2,188,550 | +577% | 0.01% | $2,341,749 |
| WELLS FARGO & COMPANY/MN | 1.5% | 2,067,046 | +62% | 0% | $2,211,739 |
| Russell Investments Group, Ltd. | 1.2% | 1,651,788 | +4.3% | 0% | $1,767,411 |
| NORTHERN TRUST CORP | 0.86% | 1,219,879 | +82% | 0% | $1,305,271 |
| PERKINS CAPITAL MANAGEMENT INC | 0.8% | 1,125,000 | -0.09% | 0.91% | $1,203,750 |
| VANGUARD FIDUCIARY TRUST CO | 0.76% | 1,068,109 | +71% | 0% | $1,142,877 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.72% | 1,022,262 | +93% | 0% | $1,093,820 |
| UBS Group AG | 0.6% | 845,314 | +90% | 0% | $904,486 |
| AQR CAPITAL MANAGEMENT LLC | 0.51% | 723,200 | +208% | 0% | $773,824 |
| RAYMOND JAMES FINANCIAL INC | 0.41% | 577,381 | +10% | 0% | $617,798 |
| Lido Advisors, LLC | 0.32% | 446,739 | +17% | 0% | $478,011 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.23% | 325,312 | +65% | 0% | $348,084 |
| XML Financial, LLC | 0.23% | 323,195 | +45% | 0.03% | $345,819 |
| Bank of New York Mellon Corp | 0.21% | 301,702 | +46% | 0% | $322,821 |
| BANK OF MONTREAL /CAN/ | 0.21% | 289,936 | +1.6% | 0% | $310,232 |
| Nuveen, LLC | 0.14% | 195,065 | +116% | 0% | $208,720 |
| Tripletail Wealth Management, LLC | 0.13% | 183,417 | 0.23% | $196,256 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 33,040,099 | $35,350,434 | +$11,854,850 | $1.07 | 79 |
| 2026 Q1 | 35,617,132 | $40,959,176 | +$3,281,459 | $1.15 | 103 |
| 2025 Q4 | 32,168,240 | $35,033,761 | -$2,670,618 | $1.09 | 88 |
| 2025 Q3 | 35,169,477 | $35,524,166 | +$16,345,920 | $1.01 | 84 |
| 2025 Q2 | 18,928,571 | $21,732,070 | +$10,810,145 | $1.15 | 70 |
| 2025 Q1 | 9,361,697 | $13,942,565 | +$9,083,709 | $1.49 | 47 |
| 2024 Q4 | 3,301,334 | $2,700,118 | +$681,674 | $0.82 | 31 |
| 2024 Q3 | 2,453,404 | $1,999,216 | +$373,764 | $0.82 | 27 |
| 2024 Q2 | 1,993,582 | $1,635,840 | -$60,859 | $0.82 | 31 |
| 2024 Q1 | 2,071,200 | $1,687,992 | +$173,028 | $0.81 | 26 |
| 2023 Q4 | 1,747,190 | $2,463,380 | -$132,319 | $1.41 | 23 |
| 2023 Q3 | 1,915,159 | $2,240,076 | +$59,719 | $1.17 | 23 |
| 2023 Q2 | 1,863,743 | $2,590,935 | +$131,895 | $1.39 | 16 |
| 2023 Q1 | 1,768,504 | $2,486,590 | -$200,456 | $1.40 | 18 |
| 2022 Q4 | 1,914,916 | $2,603,465 | -$579,811 | $1.36 | 21 |
| 2022 Q3 | 2,303,350 | $3,522,489 | -$263,904 | $1.53 | 20 |
| 2022 Q2 | 2,455,369 | $5,552,000 | -$914,258 | $2.26 | 23 |
| 2022 Q1 | 2,705,630 | $9,090,000 | -$2,655,787 | $3.36 | 30 |
| 2021 Q4 | 3,308,904 | $17,765,000 | +$14,803,000 | $5.37 | 35 |